Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|HER2 Gene Mutation|HER-2 Gene Amplification|HER2 Positive Gastric Cancer|Salivary Gland Cancer|Salivary Gland Tumor|Salivary Gland Carcinoma|Salivary Gland Neoplasms|Lung Cancer|Colo-rectal Cancer|Rare Diseases|Solid Tumor|Recurrent Gastric Cancer|Recurrent Colon Cancer|Recurrent Breast Cancer|Head and Neck Cancer|Head and Neck Carcinoma|Bladder Cancer|Cervical Cancer|Liver Cancer|Bile Duct Cancer|Urologic Cancer|Pancreatic Cancer|Prostate Cancer|Recurrent Prostate Cancer|Rectal Cancer|Recurrent Ovarian Carcinoma|Recurrent Renal Cell Cancer|Rectal Cancer Stage II|Rectal Cancer Stage I|Rectal Cancer Stage III|Skin Cancer|Mouth Cancer|Lip Cancer Stage I|Tongue Cancer|Breast Neoplasm Malignant Primary|Larynx Cancer|Tonsil Cancer|Palate Cancer|Mucoepidermoid Carcinoma|Primary Peritoneal Carcinoma|Mucinous Adenocarcinoma Gastric|Mucinous Breast Cancer Recurrent|Cholangiocarcinoma
Interventions: DRUG: A166
Sponsor: Klus Pharma Inc.